What question did this study set out to answer?

This research aims to validate mechanistic and hybrid predictive models for patient response to CDK4/6 inhibitors and endocrine treatment in HR+/HER2- breast cancer.

April 19, 2026Cancer Research

Abstract LB015: Precision biomarkers for cdk4/6 inhibitors plus endocrine treatment inHR+/HER2-breast cancer: External validation of mechanistic and hybrid predictive models across multiple neoadjuvant trials

View Full Paper

Ask AI

Bookmark

This research aims to validate mechanistic and hybrid predictive models for patient response to CDK4/6 inhibitors and endocrine treatment in HR+/HER2- breast cancer.
Developed a mechanistic model to generate patient-specific response scores based on gene expression.
Enhanced the model using machine learning to correct errors and incorporate additional molecular data.
Validated models using data from CORALLEEN, NEOPALANA, and NEOLETRIB trials, assessing response via Ki67 and PAM50 ROR scores.
The mechanistic model achieved significant predictions for high residual Ki67 levels with an AUC of 0.80 and high PAM50 ROR with an AUC of 0.78.
The hybrid model outperformed the mechanistic model by better capturing biological variability and stratifying patient responses.
Both models demonstrated drug-specific predictions without associating outcomes to chemotherapy treatments.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

External validation shows enhanced predictive accuracy of hybrid models for response in HR+/HER2- breast cancer, suggesting improved clinical decision-making.

Cite This Study

Köhn‐Luque et al. (2026) studied this question.

synapsesocial.com/papers/69e47250010ef96374d8e5b6 https://doi.org/10.1158/1538-7445.am2026-lb015

View Full Paper

Ask AI

Bookmark

Implication

External validation shows enhanced predictive accuracy of hybrid models for response in HR+/HER2- breast cancer, suggesting improved clinical decision-making.

Abstract LB015: Precision biomarkers for cdk4/6 inhibitors plus endocrine treatment inHR+/HER2-breast cancer: External validation of mechanistic and hybrid predictive models across multiple neoadjuvant trials

Key Points

Discussion

Implication

Cite This Study

Abstract LB015: Precision biomarkers for cdk4/6 inhibitors plus endocrine treatment inHR+/HER2-breast cancer: External validation of mechanistic and hybrid predictive models across multiple neoadjuvant trials

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider